Synergism and Antagonism in Chemotherapy

Abstract

Part 1 Reviews and methods of quantitation: synergism, antagonism and potentiation in chemotherapy - an overview, D.Rideout and T.-C.Chou the median effect principle and the combination index as tools for quantitation of synergism and antagonism, T.-C.Chou clinical studies of combination chemotherapy for cancer, E.Frei combined chemotherapeutic modalities for viral infections - rational and clinical potential, R.F.Schinazi antimalarial synergism and antagonism, J.L.Vennerston, et al quantitation of synergism and antagonism of two or more drugs by computerized analysis, J.Chou. Part 2 Mechanisms of interaction: potentiation through inhibition of metabolic drug inactivation - modulation of drug activity and toxicity by perturbation of glutathione metabolism, H.S.Friedman and O.W.Griffith synergy and antagonism in polymerase-targeted antiviral therapy - effects of deoxynucleoside triphosphate pool modulation on prodrug activation, T.Spector and J.A.Fyfe reversal of multidrug resistance in tumour cells, C.-P.H.Yang, et al biochemical mechanism of the synergistic interaction of antifolates acting on different enzymes of folate metabolic pathways, J.Galivan synergistic and antagonistic drug interactions resulting from multiple inhibition of metabolic pathways, R.C.Jackson enhanced effects of drugs that bind simultaneously to the same macromolecular target, L.Strekowski and W.D.Wilson modulation of 5-fluorouracil by metabolites and antimetabolites, E.Mini and J.R.Bertino synergism and antagonism through direct bond formation between two agents in situ, D.C.Rideout and T.Calogeropoulou chemotherapeutic potentiation through interaction at the level of DNA, B.A.Teicher, et al drug synergism, antagonsim and collateral sensitivity involving genetic changes, S.-H.Huang and J.S.Holcenberg. Part 3 Condition-selective synergism and antagonism: schedule-dependent effects in antineoplastic synergism and antagonsim, B.K.Chang effects of drug distribution and cellular microenvironment on the interaction of cancer chemotherapeutic agents, R.E.Durrand synergistic interactions at the solid tumour level through targeting of therapies against two or more different tumour cell subpopulations, D.W.Siemann and P.C.Keng selective synergism aganist the target versus host bone marrow progenitor cells, E.Berman and T.-T.Chang.